Cell-surface terminal β-galactoside glycan (β-Gal glycan)

Cell-surface glycans with terminal β-linked galactose are carbohydrate structures found on glycoproteins and glycolipids that play a crucial role in cellular recognition and signaling. These terminal residues, often Galβ1-4GlcNAc (N-acetyllactosamine) or Galβ1-3GalNAc, serve as primary ligands for the galectin family of proteins, which modulate immune responses, cell adhesion, and apoptosis (Varki et al., 2017). In pathological states such as cancer, the density and branching of these glycans are often altered, contributing to tumor progression and immune evasion by creating a "galectin lattice" that suppresses T-cell activity (Rabinovich & Croci, 2012). This lattice formation can also promote cell migration and metastasis by stabilizing growth factor receptors on the cell surface (Johannes et al., 2018). Therapeutically, these glycans are targeted indirectly by galectin inhibitors, such as Belapectin and GB1211, which occupy the carbohydrate-recognition domain of galectins to prevent glycan binding (Thiemann & Baum, 2016). Additionally, terminal galactose residues are recognized by the asialoglycoprotein receptor (ASGPR) in the liver, a mechanism widely exploited for the targeted delivery of therapeutic oligonucleotides and small molecules (D'Souza & Devarajan, 2015). Challenges in targeting these glycans include their ubiquitous presence across various tissues, which necessitates high specificity to avoid off-target effects (Varki et al., 2017). Monitoring the expression of these glycans and their associated binding proteins serves as a valuable biomarker for disease progression and therapeutic efficacy in fibrosis and oncology (Rabinovich & Croci, 2012).

Other names

Cell-surface glycans with terminal β-linked galactoseTerminal β-galactosideGal-terminated glycanβ-galactoside-terminated glycan

Competitive inhibition of galectin binding to terminal β-galactoside residues, thereby disrupting the galectin-glycan lattice and modulating downstream signaling pathways.